Bayesian designs for phase I-II clinical trials / Ying Yuan, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Hoang Q. Nguyen,The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Peter F. Thall The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
By: Yuan, Ying (Professor of biostatistics)
.
Contributor(s): Nguyen, Hoang Q | Thall, Peter F.
Material type: 
BookSeries: Publisher: Boca Raton : CRC Press,Taylor & Francis Group, 2016Description: xiv, 310 pages : illustrations ; 24 cm.Content type: text Media type: unmediated Carrier type: volumeISBN: 9780367828912.Subject(s): Clinical trials -- Statistical methods | Drugs -- Testing -- Statistical methods | Bayesian statistical decision theory | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Statistics as Topic | Bayes Theorem | Dose-Response Relationship, Drug | Bayesian statistical decision theory | Clinical trials -- Statistical methods | Drugs -- Testing -- Statistical methodsDDC classification: 615.50724 | Item type | Current location | Collection | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|---|
Reference
|
RGU Central Library Reference | Reference | 615.50724 YUA-B (Browse shelf) | Not for loan | 77875 |
Browsing RGU Central Library Shelves , Shelving location: Reference , Collection code: Reference Close shelf browser
|
|
|
|
|
|
|
||
| 615.3252 ITO-T Taxus | 615.403 OFF-E Encyclopedia of molecular pharmacology | 615.403 OFF-E Encyclopedia of molecular pharmacology | 615.50724 YUA-B Bayesian designs for phase I-II clinical trials / | 615.580724 HOU-D Dynamic prediction in clinical survival analysis: | 615.6 LOR-S Smart materials for drug delivery: | 615.6 LOR-S Smart materials for drug delivery: |
Includes bibliographical references (pages 283-300) and index.
Why conduct phase I-II trials? -- The phase I-II paradigm -- Establishing priors -- Efficacy-toxicity trade-off-based designs -- Designs with late-onset outcomes -- Utility-based designs -- Personalized dose finding -- Combination trials -- Optimizing molecularly targeted agents -- Optimizing doses in two cycles -- Optimizing dose and schedule -- Dealing with dropouts -- Optimizing intra-arterial tPA -- Optimizing sedative dose in preterm infants.
There are no comments for this item.